- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07797959
Thread-Embedding Acupuncture as an Adjunct to Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease
2026년 8월 28일 업데이트: Dr Nguyen Ngo Le Minh Anh MD, PhD, University of Science Ho Chi Minh City
Efficacy and Safety of Thread-Embedding Acupuncture as an Adjunct to Proton Pump Inhibitor Therapy in Patients With Gastroesophageal Reflux Disease and Liver-Stomach Stagnation-Heat Syndrome: A Randomized Controlled Trial
This study aims to evaluate the effectiveness of thread-embedding acupuncture combined with omeprazole in patients with gastroesophageal reflux disease (GERD) presenting with the traditional medicine pattern of Liver-Stomach constraint-heat.
Participants will receive either thread-embedding acupuncture combined with omeprazole or the comparator treatment according to the study protocol.
Clinical outcomes will be assessed to determine the effectiveness and safety of the intervention.
연구 개요
연구 유형
중재적
등록 (추정된)
50
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Minh-Anh Nguyen Ngo Le, MD, PhD
- 전화번호: +84 962 644 648
- 이메일: drminhanh@ump.edu.vn
연구 장소
-
-
-
Ho Chi Minh City, 베트남
- 모병
- Traditional Medicine Hospital of Ho Chi Minh City
-
연락하다:
- Hien Thu Thi Le, MD
- 전화번호: +84886725372
- 이메일: mingyingtcm@gmail.com
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Aged 18 to 60 years.
- Diagnosed with gastroesophageal reflux disease (GERD) with a GerdQ score ≥8 and typical heartburn and/or regurgitation occurring at least 2 days per week, and considered eligible for proton pump inhibitor therapy according to the ACG 2013 guideline.
- Meets the diagnostic criteria for Liver-Stomach Heat Stagnation Syndrome according to the 2017 expert consensus on traditional medicine syndrome differentiation for GERD.
- No previous diagnosis of GERD within the past 8 weeks.
- Voluntarily agrees to participate in the study and provides written informed consent.
Exclusion Criteria:
- Presence of alarm symptoms, including dysphagia, odynophagia, palpable lymph nodes or mass, unintentional weight loss, family history of gastrointestinal malignancy, gastrointestinal bleeding, anemia, or persistent nausea/vomiting.
- Structural gastrointestinal disease confirmed by endoscopy, including esophageal malignancy or other significant organic lesions.
- Current use of medications that may influence GERD assessment or treatment, including glucocorticoids, NSAIDs, bisphosphonates, prostaglandins, oral contraceptives, antifungal agents, or sedative medications.
- Use of proton pump inhibitors, H2-receptor antagonists, or prokinetic agents within the previous 14 days.
- History of hypersensitivity to proton pump inhibitors or absorbable catgut/thread material.
- Skin inflammation, infection, or other dermatologic disease at or around the intended thread-embedding sites.
- Current pregnancy or breastfeeding.
- Currently participating in another interventional clinical study.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Omeprazole
Participants receive omeprazole according to the treatment regimen specified in the study protocol.
|
Participants will receive acupoint catgut embedding in addition to standard treatment with omeprazole.
Acupoint catgut embedding will be performed twice during the 4-week treatment period, at 2-week intervals.
Sterile chromic catgut 3/0 will be embedded at Zhongwan (CV12), Shangwan (CV13), Xiawan (CV10), Zusanli (ST36), Tianshu (ST25), and Taichong (LR3) according to the standardized procedure.
Participants will be monitored for 30 minutes after each procedure for adverse events.
다른 이름들:
|
|
실험적: Thread-Embedding Acupuncture Plus Omeprazole
Participants receive thread-embedding acupuncture in combination with omeprazole according to the treatment regimen specified in the study protocol.
|
Participants will receive acupoint catgut embedding in addition to standard treatment with omeprazole.
Acupoint catgut embedding will be performed twice during the 4-week treatment period, at 2-week intervals.
Sterile chromic catgut 3/0 will be embedded at Zhongwan (CV12), Shangwan (CV13), Xiawan (CV10), Zusanli (ST36), Tianshu (ST25), and Taichong (LR3) according to the standardized procedure.
Participants will be monitored for 30 minutes after each procedure for adverse events.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in GERD-Q Score
기간: Baseline and 4 weeks
|
Gastroesophageal reflux disease symptoms will be assessed using the Gastroesophageal Reflux Disease Questionnaire (GerdQ).
The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms.
Change in the total GerdQ score from baseline to 4 weeks will be assessed between the two study groups.
|
Baseline and 4 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment Response Based on GerdQ
기간: Baseline and weekly through 4 weeks
|
Treatment response will be defined as a reduction of at least 2 points in the total Gastroesophageal Reflux Disease Questionnaire (GerdQ) score from baseline.
The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms.
The proportion of participants achieving treatment response will be compared between the two study groups.
|
Baseline and weekly through 4 weeks
|
|
Complete Symptom Resolution Based on GerdQ
기간: 4 weeks
|
Complete resolution of typical gastroesophageal reflux disease (GERD) symptoms will be assessed using the Gastroesophageal Reflux Disease Questionnaire (GerdQ).
The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe GERD symptoms.
Complete symptom resolution will be defined as a score of 0 for both the heartburn and regurgitation items of the GerdQ.
The proportion of participants achieving complete symptom resolution at 4 weeks will be compared between the two study groups.
|
4 weeks
|
|
Change in Traditional Medicine Symptoms of Liver-Stomach Heat Stagnation Syndrome
기간: Baseline and weekly through 4 weeks
|
Traditional medicine symptoms of Liver-Stomach Stagnated Heat syndrome will be assessed using a syndrome symptom score comprising two main symptoms (burning sensation and acid regurgitation) and six secondary symptoms (retrosternal pain, epigastric burning pain, epigastric fullness, belching or food regurgitation, irritability, and rapid hunger).
Each main symptom is rated as absent, mild, moderate, or severe and scored 0, 2, 4, or 6 points, respectively.
Each secondary symptom is rated as absent, mild, moderate, or severe and scored 0, 1, 2, or 3 points, respectively.
The total score ranges from 0 to 30, with higher scores indicating greater syndrome severity.
Change in the total syndrome score from baseline through 4 weeks will be compared between the two study groups.
|
Baseline and weekly through 4 weeks
|
|
Treatment Response Based on Liver-Stomach Stagnated Heat Syndrome Score
기간: Baseline and 4 weeks
|
Treatment response for Liver-Stomach Stagnated Heat syndrome will be assessed using the percentage reduction in the total syndrome score from baseline.
The efficacy index will be calculated as [(baseline score - post-treatment score) / baseline score] × 100.
Clinical cure is defined as an efficacy index of at least 95%, markedly effective as 70% to less than 95%, effective as 30% to less than 70%, and ineffective as less than 30%.
The proportion of participants classified as clinically cured, markedly effective, effective, or ineffective at 4 weeks will be compared between the two study groups.
|
Baseline and 4 weeks
|
|
Adverse Events Associated With Thread-Embedding Acupuncture
기간: Throughout the 4-week treatment period
|
Adverse events associated with thread-embedding acupuncture will be monitored throughout the 4-week treatment period.
Events of interest include local pain, bleeding, bruising, swelling, infection, allergic reactions, and other treatment-related complications.
The number and proportion of participants experiencing at least one adverse event will be recorded and compared between the two study groups.
|
Throughout the 4-week treatment period
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: Minh-Anh Nguyen Ngo Le, MD,PhD, University of Medicine and Pharmacy at Ho Chi Minh City
- 수석 연구원: Minh-Anh Nguyen Ngo Le, MD, PhD, University of Medicine and Pharmacy at Ho Chi Minh City
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2026년 4월 15일
기본 완료 (추정된)
2026년 9월 15일
연구 완료 (추정된)
2026년 9월 18일
연구 등록 날짜
최초 제출
2026년 8월 26일
QC 기준을 충족하는 최초 제출
2026년 8월 28일
처음 게시됨 (실제)
2026년 9월 1일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 9월 1일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 8월 28일
마지막으로 확인됨
2026년 8월 1일
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- TEA-GERD-RCT2026
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .